<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: Although ", fill: "#ff033e"},
{source: "6: Although ", target: "6: uncertainties", fill: "#ff033e"},
{source: "6: Although ", target: "9: incur significant", fill: "#bf94e4"},
{source: "9: incur significant", target: "9: foreseeable future", fill: "#bf94e4"},
{source: "9: foreseeable future", target: "9: profitability", fill: "#bf94e4"},
{source: "9: incur significant", target: "11: incur significant", fill: "#f984e5"},
{source: "11: incur significant", target: "11: net losses as", fill: "#f984e5"},
{source: "11: net losses as", target: "11: continue sales", fill: "#f984e5"},
{source: "11: continue sales", target: "11: marketing efforts", fill: "#f984e5"},
{source: "11: marketing efforts", target: "11: United States", fill: "#f984e5"},
{source: "11: incur significant", target: "21: dependent on", fill: "#aa4069"},
{source: "21: dependent on", target: "21: only commercial product", fill: "#aa4069"},
{source: "21: dependent on", target: "22: If the Essure ", fill: "#536878"},
{source: "22: If the Essure ", target: "22: significant", fill: "#536878"},
{source: "22: significant", target: "22: payers even", fill: "#536878"},
{source: "22: payers even", target: "22: reimbursement levels", fill: "#536878"},
{source: "22: reimbursement levels", target: "22: necessary", fill: "#536878"},
{source: "22: necessary", target: "22: international", fill: "#536878"},
{source: "22: international", target: "22: regulatory", fill: "#536878"},
{source: "22: regulatory", target: "22: profitability", fill: "#536878"},
{source: "22: If the Essure ", target: "28: future liquidity", fill: "#3d2b1f"},
{source: "28: future liquidity", target: "28: capital requirements will depend upon", fill: "#3d2b1f"},
{source: "28: capital requirements will depend upon", target: "28: among others", fill: "#3d2b1f"},
{source: "28: among others", target: "28: product adoption by doctors", fill: "#3d2b1f"},
{source: "28: product adoption by doctors", target: "28: government", fill: "#3d2b1f"},
{source: "28: government", target: "28: thirdparty reimbursement", fill: "#3d2b1f"},
{source: "28: thirdparty reimbursement", target: "28: private insurance systems as well as", fill: "#3d2b1f"},
{source: "28: private insurance systems as well as", target: "28: timeliness", fill: "#3d2b1f"},
{source: "28: timeliness", target: "28: days sales outstanding", fill: "#3d2b1f"},
{source: "28: days sales outstanding", target: "28: resources devoted", fill: "#3d2b1f"},
{source: "28: resources devoted", target: "28: increasing manufacturing capacity", fill: "#3d2b1f"},
{source: "28: increasing manufacturing capacity", target: "28: meet commercial demands", fill: "#3d2b1f"},
{source: "28: meet commercial demands", target: "28: conducting sales", fill: "#3d2b1f"},
{source: "28: conducting sales", target: "28: distribution programs", fill: "#3d2b1f"},
{source: "28: distribution programs", target: "28: product development programs", fill: "#3d2b1f"},
{source: "28: product development programs", target: "28: potential requirement", fill: "#3d2b1f"},
{source: "28: potential requirement", target: "28: royalty payments", fill: "#3d2b1f"},
{source: "28: royalty payments", target: "28: settlement agreement", fill: "#3d2b1f"},
{source: "28: future liquidity", target: "40: campaigns", fill: "#ff2800"},
{source: "40: campaigns", target: "40: contact with", fill: "#ff2800"},
{source: "40: contact with", target: "40: trained physician often involving", fill: "#ff2800"},
{source: "40: trained physician often involving", target: "40: referral from", fill: "#ff2800"},
{source: "40: referral from", target: "40: primary care", fill: "#ff2800"},
{source: "40: primary care", target: "40: birth control", fill: "#ff2800"},
{source: "40: birth control", target: "40: options by", fill: "#ff2800"},
{source: "40: options by", target: "40: preauthorized", fill: "#ff2800"},
{source: "40: preauthorized", target: "40: insurance reimbursement", fill: "#ff2800"},
{source: "40: campaigns", target: "46: Government ", fill: "#000f89"},
{source: "46: Government ", target: "46: reimbursement", fill: "#000f89"},
{source: "46: reimbursement", target: "46: for the Essure ", fill: "#000f89"},
{source: "46: for the Essure ", target: "46: procedure may", fill: "#000f89"},
{source: "46: procedure may", target: "46: which would limit", fill: "#000f89"},
{source: "46: which would limit", target: "46: future product", fill: "#000f89"},
{source: "46: future product", target: "46: profitability", fill: "#000f89"},
{source: "46: Government ", target: "62: by foreign countries", fill: "#7b3f00"},
{source: "62: by foreign countries", target: "62: shorter than", fill: "#7b3f00"},
{source: "62: shorter than", target: "62: requirements", fill: "#7b3f00"},
{source: "62: requirements", target: "62: licensing may differ significantly from", fill: "#7b3f00"},
{source: "62: by foreign countries", target: "71: foreign countries", fill: "#007fbf"},
{source: "71: foreign countries", target: "71: proprietary", fill: "#007fbf"},
{source: "71: proprietary", target: "71: same extent as", fill: "#007fbf"},
{source: "71: same extent as", target: "71: United States ", fill: "#007fbf"},
{source: "71: United States ", target: "71: encountered", fill: "#007fbf"},
{source: "71: encountered", target: "71: significant", fill: "#007fbf"},
{source: "71: foreign countries", target: "73: technology from unauthorized use by", fill: "#ff91a4"},
{source: "73: technology from unauthorized use by", target: "73: covered by valid", fill: "#ff91a4"},
{source: "73: covered by valid", target: "73: enforceable patents", fill: "#ff91a4"},
{source: "73: enforceable patents", target: "73: effectively", fill: "#ff91a4"},
{source: "73: effectively", target: "73: as trade secrets", fill: "#ff91a4"},
{source: "73: technology from unauthorized use by", target: "START_HERE", fill: "#ff91a4"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profit_(economics)">Profit (economics)</a></td>
      <td>An economic profit is the difference between the revenue a  commercial entity has received from its outputs and the opportunity costs of its inputs. It equals to total revenue minus total cost, including both explicit and implicit costs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_analysis">Profitability analysis</a></td>
      <td>In cost accounting, profitability analysis is an analysis of the profitability of an organisation's output. Output of an organisation can be grouped into products, customers, locations, channels and/or transactions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_profitability">Customer profitability</a></td>
      <td>Customer profitability (CP) is the profit the firm makes from serving a customer or customer group over a specified period of time, specifically the difference between the revenues earned from and the costs associated with the customer relationship in a specified period. According to Philip Kotler,"a profitable customer is a person, household or a company that overtime, yields a revenue stream that exceeds by an acceptable amount the company's cost stream of attracting, selling and servicing the customer."\nCalculating customer profit is an important step in understanding which customer relationships are better than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitable_growth">Profitable growth</a></td>
      <td>Profitable Growth is the combination of profitability and growth, more precisely the combination of Economic Profitability and Growth of Free cash flows. Profitable growth is aimed at seducing the financial community; it emerged in the early 80s when shareholder value creation became firms’ main objective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_Profitability_Analysis">Customer Profitability Analysis</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/SAP_ERP">SAP ERP</a></td>
      <td>SAP ERP is an enterprise resource planning software developed by the German company SAP SE. SAP ERP incorporates the key business functions of an organization. The latest version of SAP ERP (V.6.0) was made available in 2006.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porter's_five_forces_analysis">Porter's five forces analysis</a></td>
      <td>Porter's Five Forces Framework is a method of analysing the operating environment of a competition of a business. It draws from industrial organization (IO) economics to derive five forces that determine the competitive intensity and, therefore, the attractiveness (or lack thereof) of an industry in terms of its profitability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Net_income">Net income</a></td>
      <td>In business and accounting, net income (also total comprehensive income, net earnings, net profit, bottom line, sales profit, or credit sales) is an entity's income minus cost of goods sold, expenses, depreciation and amortization, interest, and taxes for an accounting period.It is computed as the residual of all revenues and gains less all expenses and losses for the period, and has also been defined as the net increase in shareholders' equity that results from a company's operations. It is different from gross income, which only deducts the cost of goods sold from revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Democratic_Party_(United_States)">Democratic Party (United States)</a></td>
      <td>The Democratic Party is one of the two major contemporary political parties in the United States. It was founded in 1828 by supporters of Andrew Jackson, making it the world's oldest active political party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_software">Proprietary software</a></td>
      <td>Proprietary software, also known as non-free software or closed-source software, is computer software for which the software's publisher or another person reserves some licensing rights to use, modify, share modifications, or share the software, restricting user freedom with the software they lease. It is the opposite of open-source or free software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_reimbursement_account">Health reimbursement account</a></td>
      <td>A Health Reimbursement Account, formally a Health Reimbursement Arrangement (HRA), is a type of US employer-funded health benefit plan that reimburses employees for out-of-pocket medical expenses and, in limited cases, to pay for health insurance plan premiums.An HRA is not truly an account, since it does not place funds under a separate legal title. Instead, it is an agreement under which the employee can submit qualified health expenses to the employer for reimbursement.Following implementation of the Affordable Care Act, HRAs must be integrated with a qualified employer-sponsored group health insurance plan to avoid excise tax penalties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitation_(healthcare)">Capitation (healthcare)</a></td>
      <td>Capitation is a payment arrangement for health care service providers. It pays a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diagnosis-related_group">Diagnosis-related group</a></td>
      <td>Diagnosis-related group (DRG) is a system to classify hospital cases into one of originally 467 groups, with the last group (coded as 470 through v24, 999 thereafter) being "Ungroupable". This system of classification was developed as a collaborative project by Robert B Fetter, PhD, of the Yale School of Management, and John D. Thompson, MPH, of the Yale School of Public Health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_United_States_citizens">Visa requirements for United States citizens</a></td>
      <td>As of 25 February 2022, Holders of a United States passport could travel to 186 countries and territories without a travel visa, or with a visa on arrival. The United States passport currently ranks 6th in terms of travel freedom (tied with the passports of Czech Republic, Greece, Malta, Norway, and the UK) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_British_citizens">Visa requirements for British citizens</a></td>
      <td>Visa requirements for British citizens are administrative entry restrictions by the authorities of other states placed on citizens of the United Kingdom. As of 30 April 2022, British citizens had visa-free or visa on arrival access to 187 countries and territories, ranking their passport 5th in terms of travel freedom (tied with France, Ireland and Portugal) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirement">Requirement</a></td>
      <td>In product development and process optimization, a requirement is a singular documented physical or functional need that a particular design, product or process aims to satisfy. It is commonly used in a formal sense in engineering design, including for example in systems engineering, software engineering, or enterprise engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_analysis">Requirements analysis</a></td>
      <td>In systems engineering and software engineering, requirements analysis focuses on the tasks that determine the needs or conditions to meet the new or altered product or project, taking account of the possibly conflicting requirements of the various stakeholders, analyzing, documenting, validating and managing software or system requirements.Requirements analysis is critical to the success or failure of a systems or software project. The requirements should be documented, actionable, measurable, testable, traceable, related to identified business needs or opportunities, and defined to a level of detail sufficient for system design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reimbursement">Reimbursement</a></td>
      <td>Reimbursement is the act of compensating someone for an out-of-pocket expense by giving them an amount of money equal to what was spent.Companies, governments and nonprofit organizations may compensate their employees or officers for necessary and reasonable expenses; under US\nlaw, these expenses may be deducted from taxes by the organization and treated as untaxed income for the recipient provided that accountability conditions are met. UK law provides for deductions for travel and subsistence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_mileage_reimbursement_rate">Business mileage reimbursement rate</a></td>
      <td>The business mileage reimbursement rate is an optional standard mileage rate used in the United States for purposes of computing the allowable business deduction, for Federal income tax purposes under the Internal Revenue Code, at 26 U.S.C. § 162, for the business use of a vehicle. Under the law, the taxpayer for each year is generally entitled to deduct either the actual expense amount, or an amount computed using the standard mileage rate, whichever is greater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ERISA_reimbursement">ERISA reimbursement</a></td>
      <td>In the United States, ERISA reimbursement refers to the efforts of an ERISA Plan administrator (an insurer) to obtain repayment from an insured person who had previously received payments for personal injury medical bills.When an insurer pays a injury claim to someone, the insurer can seize cash settlements from whoever caused the injury. This “right of reimbursement” is essentially a subrogation claim.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fee_Reimbursement_Scheme_(Andhra_Pradesh)">Fee Reimbursement Scheme (Andhra Pradesh)</a></td>
      <td>The Fee Reimbursement Scheme (also known as the Post-matric Scholarship Scheme) is a student education sponsorship programme of the Government of Andhra Pradesh. It supports students from lower economic strata in the state.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-functional_requirement">Non-functional requirement</a></td>
      <td>In systems engineering and requirements engineering, a non-functional requirement (NFR) is a requirement that specifies criteria that can be used to judge the operation of a system, rather than specific behaviours. They are contrasted with functional requirements that define specific behavior or functions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Age_of_candidacy">Age of candidacy</a></td>
      <td>Age of candidacy is the minimum age at which a person can legally hold certain elected government offices. In many cases, it also determines the age at which a person may be eligible to stand for an election or be granted ballot access.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_elicitation">Requirements elicitation</a></td>
      <td>In requirements engineering, requirements elicitation is the practice of researching and discovering the requirements of a system from users, customers, and other stakeholders. The practice is also sometimes referred to as "requirement gathering".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_protocol">Proprietary protocol</a></td>
      <td>In telecommunications, a proprietary protocol is a communications protocol owned by a single organization or individual.\n\n\n== Intellectual property rights and enforcement ==\nOwnership by a single organization gives the owner the ability to place restrictions on the use of the protocol and to change the protocol unilaterally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_firmware">Proprietary firmware</a></td>
      <td>Proprietary firmware is any firmware on which is not free (libre). Examples of proprietary works include ones upon which the author has placed restrictions on use, private modification, copying, or republishing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CONCEPTUS INC      ITEM 1A RISK FACTORS                  In  addition  to  the other information in this Form 10-K, the     <font color="blue">following factors should</font> be considered <font color="blue">carefully</font> in evaluating <font color="blue">Conceptus </font>and     our business</td>
    </tr>
    <tr>
      <td><font color="blue">This Form </font>10-K contains forward-looking statements within the     meaning  of  section 27A of the <font color="blue">Securities Act </font>of 1933, as amended and     section 21E <font color="blue">of the Securities Exchange Act </font>of 1934, as amended</td>
    </tr>
    <tr>
      <td>Some of the     forward-looking statements can be identified by use of forward-looking words     such as  &amp;quote believes, &amp;quote   &amp;quote expects, &amp;quote   &amp;quote anticipates, &amp;quote   &amp;quote may, &amp;quote   &amp;quote will, &amp;quote   &amp;quote should, &amp;quote       &amp;quote seeks, &amp;quote   &amp;quote approximates, &amp;quote   &amp;quote intends, &amp;quote   &amp;quote plans, &amp;quote  or  &amp;quote estimates, &amp;quote  or the negative     of these words, or other <font color="blue">comparable terminology</font></td>
    </tr>
    <tr>
      <td>The discussion of financial     trends, strategy, plans or <font color="blue">intentions may also</font> include forward-looking     statements</td>
    </tr>
    <tr>
      <td>Forward-looking <font color="blue">statements involve risks</font> and <font color="blue">uncertainties</font> that     could  cause actual results to <font color="blue">differ materially from</font> those projected</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>it is not possible to predict or identify all such risks and     <font color="blue">uncertainties</font>, they may include, but are not limited to, the following     factors</td>
    </tr>
    <tr>
      <td>The  readers  should not consider this list to be a complete     statement of all <font color="blue">potential risks</font> and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>We have a limited history of <font color="blue">operation with</font> <font color="blue">the Essure </font>system and     have <font color="blue">incurred <font color="blue">significant</font></font> operating <font color="blue">losses since inception</font></td>
    </tr>
    <tr>
      <td>We expect to     <font color="blue">incur <font color="blue">significant</font></font> operating losses for the <font color="blue">foreseeable future</font> and we may     never achieve or maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have a limited history of <font color="blue">operation with</font> <font color="blue">the Essure </font>system and     have <font color="blue">incurred <font color="blue">significant</font></font> operating losses since our inception in 1992,     including  operating  losses of dlra22dtta7 million in the fiscal year 2005,     dlra26dtta6 million in fiscal 2004 and dlra40dtta2 million in fiscal 2003</td>
    </tr>
    <tr>
      <td>We expect to     continue  to <font color="blue">incur <font color="blue">significant</font></font> operating expenses and <font color="blue">net losses as</font> we     <font color="blue">continue sales</font> and <font color="blue">marketing efforts</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our net losses     <font color="blue">will continue until sufficient revenues</font> can be generated to offset these     expenses</td>
    </tr>
    <tr>
      <td>We may not be able to generate these revenues, and we may never     achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our failure to achieve and sustain <font color="blue">profitability</font>     <font color="blue">would negatively impact</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We are presently a one-product company and if our <font color="blue">product fails</font> to     <font color="blue">gain market <font color="blue">acceptance</font></font>, our business will suffer</td>
    </tr>
    <tr>
      <td>We  are  attempting  to  introduce  a  novel  <font color="blue">product into</font> the     <font color="blue">contraception</font>  market,  which is <font color="blue">dominated by procedures</font> that are well     <font color="blue">established among physicians</font> and patients and are <font color="blue">routinely taught</font> to new     physicians</td>
    </tr>
    <tr>
      <td>As a result, we believe that <font color="blue">recommendations</font> and <font color="blue">endorsements</font> by     <font color="blue">physicians will</font> be essential for market <font color="blue">acceptance</font> of our product</td>
    </tr>
    <tr>
      <td>We do not     know whether physicians and <font color="blue">patients will accept</font> our product or whether we     will be able to obtain their <font color="blue">recommendations</font> or <font color="blue">endorsements</font> in sufficient     amounts to be profitable</td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">physicians will</font> not use a product     unless they determine, <font color="blue">based on clinical data</font> and other factors, that it is     an <font color="blue">attractive alternative</font> to other means of <font color="blue">contraception</font> and that it offers     <font color="blue">clinical utility</font> in a cost-<font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>are <font color="blue">traditionally</font>     slow  to <font color="blue">adopt new products</font> and treatment practices, partly because of     perceived <font color="blue"><font color="blue">liability</font> risks</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> <font color="blue">the Essure </font>system, which is     currently our <font color="blue">only commercial product</font></td>
    </tr>
    <tr>
      <td><font color="blue">If <font color="blue">the Essure </font></font>system does not achieve     <font color="blue">significant</font> market <font color="blue">acceptance</font> among physicians, patients and healthcare     payers, even if <font color="blue"><font color="blue">reimbursement</font> levels</font> are sufficient and <font color="blue">necessary</font> United     States and <font color="blue">international</font> <font color="blue">regulatory</font> approvals are maintained, we may never     achieve <font color="blue">significant</font> revenues or <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future liquidity</font> and <font color="blue">capital <font color="blue">requirements</font></font> are uncertain</td>
    </tr>
    <tr>
      <td>As we <font color="blue">commercialize</font> <font color="blue">the Essure </font>system on a wide-scale basis, we may     require <font color="blue"><font color="blue">additional</font> financing</font> and <font color="blue">therefore may</font> in the <font color="blue">future seek</font> to raise     <font color="blue">additional</font> funds through bank facilities, debt or <font color="blue">equity offerings</font> or other     sources of capital</td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">additional</font> equity financing may</font> be dilutive to     <font color="blue">stockholders</font>, and <font color="blue">debt financing</font>, if available, may involve restrictive     covenants and <font color="blue">interest expenses</font> that will affect our financial results</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">funding may</font> not be available when needed or on terms acceptable     to us</td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue"><font color="blue">additional</font> capital</font>, we may be required to     delay, reduce the scope of or                                         20       _________________________________________________________________       eliminate our selling and <font color="blue">marketing activities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future liquidity</font> and     <font color="blue">capital <font color="blue">requirements</font></font> will depend upon many factors, including, <font color="blue">among others</font>:          •                 the rate of <font color="blue">product adoption by doctors</font> and patients;          •                 obtaining <font color="blue">government</font> and third-party <font color="blue">reimbursement</font> for the                 Essure procedure;          •                 the liquidity of private insurance systems, as well as the                 <font color="blue">timeliness</font> of payments of <font color="blue">government</font>-management <font color="blue">reimbursement</font>                 systems;          •                 our ability to improve our <font color="blue">days sales outstanding</font>;          •                 the <font color="blue">resources devoted</font> to <font color="blue">increasing manufacturing capacity</font> to                 <font color="blue">meet commercial demands</font>;          •                 our ability to reduce our cost of sales;          •                 the <font color="blue">resources devoted</font> to developing and <font color="blue">conducting sales</font> and                 marketing and <font color="blue">distribution programs</font>;          •                 the progress and cost of <font color="blue">product <font color="blue">development</font> programs</font>; and          •                 the <font color="blue">potential requirement</font> to make <font color="blue">royalty payments</font> subject to                 the Ovion-<font color="blue">Conceptus </font><font color="blue">settlement <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>If the <font color="blue"><font color="blue">effective</font>ness</font> and safety of our product are not supported by     long-term data, we may not achieve market <font color="blue">acceptance</font> and we could be subject     to <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td><font color="blue">In September </font>2005, the Company received from the US Food and Drug     Administration, or FDA, approval to terminate the Companyapstas post-approval     <font color="blue">study with physicians newly trained</font> in performing <font color="blue">the Essure </font><font color="blue">procedure due</font>     to  the  positive  <font color="blue">placement data</font> obtained to date</td>
    </tr>
    <tr>
      <td>The purpose of the     post-approval study, required by FDA as a condition of the November 2002     approval of <font color="blue">the Essure </font>system, was to determine the rate of successful     <font color="blue">bilateral placements</font> of <font color="blue">the Essure </font>micro-inserts at first attempt with a     large number of <font color="blue">newly trained physicians</font> who were not part of the previous     clinical  studies</td>
    </tr>
    <tr>
      <td>Although treatment of the total number of patients     required by FDA had not been completed, the data obtained to <font color="blue">date provided</font>     the Company with the ability to request an <font color="blue">early termination</font> of the study</td>
    </tr>
    <tr>
      <td>Nevertheless, the long-term results of using <font color="blue">the Essure </font>device will     not  be  available for <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>If long-term studies or clinical     experience indicate that <font color="blue">the Essure </font>system is <font color="blue">less <font color="blue">effective</font></font> or less safe     than  our  current  data suggest, we may not achieve or <font color="blue">sustain market</font>     <font color="blue">acceptance</font> and/or we could be subject to <font color="blue">significant</font> <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">agreement</font>s</font> and <font color="blue">contracts <font color="blue">entered into</font> with partners</font> and other     <font color="blue"><font color="blue">third parties</font> may</font> not be successful</td>
    </tr>
    <tr>
      <td>We signed in the past and may pursue in the <font color="blue">future contracts</font> and     <font color="blue"><font color="blue">agreement</font>s</font>  with  third  parties  that  would  assist  our  marketing,     manufacturing, selling and <font color="blue">distribution efforts</font></td>
    </tr>
    <tr>
      <td>There can be <font color="blue">no assurances</font>     that, if these <font color="blue"><font color="blue">agreement</font>s</font> are <font color="blue">entered into</font> in the future, they will be     successful</td>
    </tr>
    <tr>
      <td>Our <font color="blue">advertising <font color="blue">campaigns</font> may</font> not be successful</td>
    </tr>
    <tr>
      <td>Our advertising programs, which are <font color="blue">aimed at increasing consumer</font>     awareness for our product, are <font color="blue"><font color="blue">generally</font> expensive</font> and may have limited     success, if any</td>
    </tr>
    <tr>
      <td>Such <font color="blue">campaigns</font> require consumers to make <font color="blue">contact with</font> an     Essure trained physician, often involving a <font color="blue">referral from</font> their <font color="blue">primary care</font>     physician  and then to be provided information regarding <font color="blue">birth control</font>     <font color="blue">options by</font> the physician, be pre-authorized for <font color="blue">insurance <font color="blue">reimbursement</font></font> and     then be scheduled for the procedure</td>
    </tr>
    <tr>
      <td>Many of these steps are not within our     control, and the <font color="blue">program may</font> not result in <font color="blue">revenue generation commensurate</font>     with its costs</td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________               We <font color="blue">depend on</font> our <font color="blue">contract <font color="blue">manufacture</font>r</font> to supply our commercial     <font color="blue">product <font color="blue">requirements</font></font> and we may experience <font color="blue">disruption</font> in supply if they are     not in <font color="blue">compliance with</font> FDA and other <font color="blue">health authority <font color="blue">regulations</font></font> or if our     <font color="blue">manufacture</font>rapstas business fails to succeed</td>
    </tr>
    <tr>
      <td>In April 2004, we received FDA approval to <font color="blue">begin manufacturing</font> the     Essure <font color="blue">product at</font> Accellent, Inc, or Accellent, <font color="blue">formerly named</font> Venusa, our     third-party subcontractor located in Mexico</td>
    </tr>
    <tr>
      <td>We <font color="blue">transitioned almost</font> all of     our <font color="blue">internal manufacturing <font color="blue">operations</font></font> to <font color="blue">Accellent </font>by the end of 2004 to     <font color="blue">manufacture</font> the <font color="blue">components</font> and assemble our product</td>
    </tr>
    <tr>
      <td>If <font color="blue">Accellent </font>does not     comply  with  FDA and other <font color="blue">health authority <font color="blue">regulations</font></font> or <font color="blue">encounters</font>     <font color="blue">manufacturing difficulties</font>, this <font color="blue">could negatively impact sales</font> of <font color="blue">the Essure </font>    system</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>or <font color="blue">third party</font> <font color="blue">reimbursement</font> for <font color="blue">the Essure </font><font color="blue">procedure may</font>     not be available or may be inadequate, <font color="blue">which would limit</font> our <font color="blue">future product</font>     revenues and delay or prevent our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> of <font color="blue">the Essure </font>system in the <font color="blue">United States</font> and in     <font color="blue">international</font>  markets  will  depend  in part upon the <font color="blue">availability</font> of     <font color="blue">reimbursement</font> within prevailing healthcare payment systems</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement     </font>systems in <font color="blue">international</font> markets vary <font color="blue">significant</font>ly by country and sometimes     by   region,  and  <font color="blue">reimbursement</font>  approvals  must  be  obtained  on  a     country-by-country basis</td>
    </tr>
    <tr>
      <td>Many <font color="blue">international</font> markets have <font color="blue">government</font>-managed     health  care  systems that determine <font color="blue">reimbursement</font> for new devices and     procedures</td>
    </tr>
    <tr>
      <td>In most markets, there are <font color="blue">private insurance systems as well as</font>     <font color="blue">government</font>-managed systems</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of the type of <font color="blue">reimbursement</font> system,     we believe that <font color="blue">physician advocacy</font> of our <font color="blue">product will</font> be required to obtain     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Availability </font>and extent of continued <font color="blue">reimbursement</font> will     depend, at least in part, on the clinical and cost <font color="blue"><font color="blue">effective</font>ness</font> of our     product</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">reimbursement</font> for our <font color="blue">product will</font>     continue to be available in the <font color="blue">United States</font> or in <font color="blue">international</font> markets     under either <font color="blue">government</font> or private <font color="blue">reimbursement</font> systems, or that physicians     <font color="blue">will support</font> and advocate <font color="blue">reimbursement</font> for use of our product for all     <font color="blue">indications</font>  intended  by  us</td>
    </tr>
    <tr>
      <td>We may be unable to obtain or maintain     <font color="blue">reimbursement</font>  in  any  country  within a particular time frame, for a     <font color="blue">particular amount</font>, or at all, <font color="blue">which would limit</font> our <font color="blue">future product</font> revenues     and delay or prevent our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We may not maintain <font color="blue">regulatory</font> approvals for <font color="blue">the Essure </font>system, our     only  product, which would delay or <font color="blue"><font color="blue"><font color="blue">prevent us from</font> generating</font> product</font>     revenues, and would harm our business and force us to curtail or cease     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Numerous <font color="blue">government</font> <font color="blue">authorities</font>, both in the <font color="blue">United States</font> and     <font color="blue">international</font>ly, regulate the <font color="blue">manufacture</font> and sale of <font color="blue">medical devices</font>,     including <font color="blue">the Essure </font>system</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, the principal <font color="blue">regulatory</font>     <font color="blue">authorities</font>  are the FDA and <font color="blue">corresponding</font> state agencies, such as the     <font color="blue">California Department of Health Services</font></td>
    </tr>
    <tr>
      <td>The process of obtaining and     maintaining  required  <font color="blue">regulatory</font> clearances is lengthy, expensive and     uncertain</td>
    </tr>
    <tr>
      <td>We have received FDA approval to market <font color="blue">the Essure </font>system in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If we lose that approval or fail to <font color="blue">comply with existing</font> or     future <font color="blue">regulatory</font> <font color="blue">requirements</font>, it would delay or <font color="blue"><font color="blue">prevent us from</font> generating</font>     <font color="blue">further product revenues</font></td>
    </tr>
    <tr>
      <td>Sales of <font color="blue">medical devices</font> outside of the <font color="blue">United States</font> are subject to     <font color="blue">international</font> <font color="blue">regulatory</font> <font color="blue">requirements</font> that <font color="blue">vary widely from country</font> to     country</td>
    </tr>
    <tr>
      <td>The time required to obtain clearance required <font color="blue">by <font color="blue">foreign countries</font></font>     may  be  longer  or  <font color="blue">shorter than</font> that required for FDA clearance, and     <font color="blue">requirements</font> for licensing may differ <font color="blue">significant</font>ly from FDA <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Many countries in which we <font color="blue">currently market</font> or intend to market <font color="blue">the Essure </font>    system either do not <font color="blue">currently regulate <font color="blue">medical devices</font></font> or have minimal     <font color="blue">registration</font>  <font color="blue">requirements</font>;  however, these <font color="blue">countries may</font> develop more     extensive <font color="blue">regulations</font> in the future, which <font color="blue">could delay</font> or <font color="blue">prevent us from</font>     marketing <font color="blue">the Essure </font>system in these countries</td>
    </tr>
    <tr>
      <td>The FDA and certain foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> impose numerous     <font color="blue">requirements</font> with which medical device <font color="blue">manufacture</font>rs must comply in order to     maintain <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>FDA                                         22       _________________________________________________________________       <font color="blue">enforcement policy strictly prohibits</font> the promotion of approved medical     devices for uses other than those for which the device is <font color="blue">specifically</font>     approved  by  the FDA We will be required to adhere to applicable FDA     <font color="blue">regulations</font>, such as the Quality System Regulation, and similar <font color="blue">regulations</font>     in  other  countries, which include testing, control and <font color="blue">documentation</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Ongoing <font color="blue">compliance with</font> the <font color="blue">Quality System Regulation </font>and     other applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> will be monitored through periodic     <font color="blue">inspections</font>  by  federal and state agencies, including the FDA and the     <font color="blue">California Department of Health Services</font>, and by comparable agencies in     other  countries</td>
    </tr>
    <tr>
      <td>If  we  fail  to  comply with applicable <font color="blue">regulatory</font>     <font color="blue">requirements</font>, we may be subject to, among other things, warning letters,     fines, injunctions, civil penalties, recall or seizure of products, total or     partial  suspension  of production, refusal of the <font color="blue">government</font> to grant     pre-market clearance or pre-market approval for devices, withdrawal of     approvals and <font color="blue">criminal <font color="blue">prosecution</font></font>, any of <font color="blue">which could negatively impact</font> our     business</td>
    </tr>
    <tr>
      <td>Our  intellectual  property  <font color="blue">rights may</font> not <font color="blue">provide <font color="blue">meaningful</font></font>     <font color="blue">commercial protection</font> for our product, which could enable <font color="blue">third parties</font> to     use our <font color="blue">technology</font>, or very similar <font color="blue">technology</font>, and <font color="blue">could impair</font> our ability     to compete in the market</td>
    </tr>
    <tr>
      <td>We rely on patent, copyright, trade secret and <font color="blue">trademark laws</font> to     limit the ability of others to <font color="blue"><font color="blue">compete with</font> us using</font> the same or similar     <font color="blue">technology</font> in the <font color="blue">United States</font> and other countries</td>
    </tr>
    <tr>
      <td>However, as described     below, these <font color="blue">laws afford only</font> limited protection and may not <font color="blue">adequately</font>     protect  our rights to the extent <font color="blue">necessary</font> to sustain any <font color="blue">competitive</font>     advantage we may have</td>
    </tr>
    <tr>
      <td>The laws of some <font color="blue">foreign countries</font> do not protect     <font color="blue">proprietary</font> rights to the <font color="blue">same extent as</font> the laws of the <font color="blue">United States</font>, and     many companies have <font color="blue">encountered</font> <font color="blue">significant</font> problems in protecting their     <font color="blue">proprietary</font> rights abroad</td>
    </tr>
    <tr>
      <td>These problems can be caused by the absence of     rules and methods for <font color="blue">defending <font color="blue">intellectual property</font> rights</font></td>
    </tr>
    <tr>
      <td>We will be able to protect our <font color="blue">technology</font> from <font color="blue">unauthorized</font> use by     third  parties  only  to the extent that they are <font color="blue"><font color="blue">covered by</font> valid</font> and     <font color="blue">enforceable patents</font> or are <font color="blue"><font color="blue">effective</font>ly</font> maintained <font color="blue">as <font color="blue">trade secrets</font></font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">patent positions</font> of companies developing <font color="blue">medical devices</font>, including our     patent position, <font color="blue">generally</font> are uncertain and <font color="blue">involve <font color="blue">complex legal</font></font> and     factual <font color="blue">questions concerning</font> the <font color="blue">enforceability</font> of <font color="blue">such patents against</font>     alleged <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Recent <font color="blue">judicial decisions</font> have <font color="blue">established new case</font>     law and a <font color="blue">reinterpretation</font> of <font color="blue">previous patent case law</font>, and <font color="blue">consequently</font> we     <font color="blue">cannot assure</font> you that <font color="blue">historical legal standards surrounding</font> the questions     of <font color="blue">infringement</font> and <font color="blue">validity will</font> be applied in <font color="blue">future cases</font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue"><font color="blue">legislation</font> may</font> be pending in <font color="blue">United States</font> Congress that, if enacted in its     present form, may limit the ability of medical device <font color="blue">manufacture</font>rs in the     future to obtain <font color="blue">patents on surgical</font> and <font color="blue">medical procedures</font> that are not     performed by, or as a part of, devices or <font color="blue">compositions</font> that are <font color="blue">themselves</font>     patentable</td>
    </tr>
    <tr>
      <td>Our ability to protect our <font color="blue">proprietary</font> methods and procedures     may  be  <font color="blue"><font color="blue">compromised</font> by</font> the <font color="blue">enactment</font> of this <font color="blue">legislation</font> or any other     <font color="blue">limitation</font> or reduction in the <font color="blue">patentability</font> of medical and <font color="blue">surgical methods</font>     and procedures</td>
    </tr>
    <tr>
      <td>Changes in either the <font color="blue">patent laws</font> or in <font color="blue">interpretations</font> of     <font color="blue">patent laws</font> in the <font color="blue">United States</font> and other <font color="blue">countries may</font> therefore diminish     the value of our <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>We own, or <font color="blue">control through licenses</font>, a variety of <font color="blue">issued patents</font> and     <font color="blue">pending patent <font color="blue"><font color="blue">application</font>s</font></font></td>
    </tr>
    <tr>
      <td>However, the patents on which we rely may be     challenged and invalidated, and our patent <font color="blue"><font color="blue">application</font>s</font> may not result in     <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>Moreover, our patents and patent <font color="blue"><font color="blue">application</font>s</font> may not be     <font color="blue">sufficiently broad</font> to <font color="blue">prevent others from practicing</font> our <font color="blue">technologies</font> or     from developing <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>We also face the risk that <font color="blue">others may</font>     <font color="blue">independently</font> develop similar or alternative <font color="blue">technologies</font> or <font color="blue">design around</font>     our patented <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We  have  taken  security  measures to protect our <font color="blue">proprietary</font>     information, especially <font color="blue">proprietary</font> information that is not <font color="blue">covered by</font>     patents or patent <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>These measures, however, may not provide     <font color="blue">adequate protection</font> of our <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>We  seek  to  protect  our  <font color="blue">proprietary</font>  information  <font color="blue">by entering into</font>     confidentiality <font color="blue"><font color="blue">agreement</font>s</font> with employees, collaborators and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>Nevertheless, employees, collaborators or <font color="blue">consultants</font> could still disclose     our <font color="blue">proprietary</font> information and we may not be able to protect our trade     secrets in a <font color="blue">meaningful</font> way</td>
    </tr>
    <tr>
      <td>If we                                         23       _________________________________________________________________       lose  any  employees,  we  may not be able to prevent the <font color="blue">unauthorized</font>     <font color="blue">disclosure</font> or use of our <font color="blue">technical knowledge</font> or other <font color="blue">trade secrets</font> by those     former   employees  despite  the  existence  of  a  non<font color="blue">disclosure</font>  and     <font color="blue">confidentiality <font color="blue">agreement</font></font> and other <font color="blue">contractual restrictions designed</font> and     intended to protect our <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">others may</font>     <font color="blue">independently</font> develop substantially equivalent <font color="blue">proprietary</font> information or     <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Our ability to compete <font color="blue"><font color="blue">effective</font>ly</font> will depend substantially on our     ability to develop and maintain <font color="blue">proprietary</font> aspects of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">issued patents</font>, any <font color="blue">future patents</font> that may be issued as a result of our     <font color="blue">United States</font> or foreign patent <font color="blue"><font color="blue">application</font>s</font>, or the <font color="blue">patents under which</font> we     have  license  rights  may  not offer any degree of <font color="blue">protection against</font>     <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>Any patents that may be issued or licensed to us or     any  of  our  patent  <font color="blue"><font color="blue">application</font>s</font> could be challenged, invalidated or     <font color="blue">circumvented</font> in the future</td>
    </tr>
    <tr>
      <td>If we cannot operate our business without infringing third-party     <font color="blue">intellectual property</font> rights, our <font color="blue">prospects will suffer</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to operate without     infringing or <font color="blue">misappropriating</font> the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>We may be     exposed to <font color="blue">future <font color="blue">litigation</font> by <font color="blue">third parties</font> based on</font> claims that our     <font color="blue">product infringes</font> the <font color="blue">intellectual property</font> rights of others</td>
    </tr>
    <tr>
      <td>There are     numerous <font color="blue">issued patents</font> in the medical device industry and, as described in     the next risk factor, the validity and breadth of medical device patents     involve  <font color="blue">complex legal</font> and factual questions for <font color="blue">which important legal</font>     <font color="blue">principles remain unresolved</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors may</font> assert that our product     and the methods we <font color="blue">employ may</font> be <font color="blue">covered by</font> <font color="blue">United States</font> or foreign patents     held by them</td>
    </tr>
    <tr>
      <td>In addition, because patent <font color="blue"><font color="blue">application</font>s</font> can take many years     to issue, there may be currently <font color="blue">pending patent <font color="blue"><font color="blue">application</font>s</font></font> of which we are     unaware  that  may later result in <font color="blue">issued patents</font> that our <font color="blue">product may</font>     infringe</td>
    </tr>
    <tr>
      <td>There <font color="blue">could also</font> be <font color="blue">existing patents</font> of which we are unaware that     our <font color="blue">product may</font> inadvertently infringe</td>
    </tr>
    <tr>
      <td>If we lose a patent <font color="blue">infringement</font>     lawsuit, we could be <font color="blue">prevented from selling</font> our product unless we can obtain     a license to use <font color="blue">technology</font> or ideas <font color="blue">covered by</font> that patent or are able to     redesign the product to avoid <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">license may</font> not be available     to  us on terms acceptable to us, or at all, and we may not be able to     redesign our product to avoid any <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>If we are not successful in     obtaining a license or <font color="blue">redesigning</font> our product, we may be unable to sell our     product and our business <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>We  have  been,  and  may  be in the future, a party to patent     <font color="blue">litigation</font>, which could be expensive and divert our managementapstas attention</td>
    </tr>
    <tr>
      <td>The medical device industry has <font color="blue">been characterized by</font> extensive     <font color="blue">litigation</font> regarding patents and other <font color="blue">intellectual property</font> rights, and     companies in the industry have used <font color="blue">intellectual property</font> <font color="blue">litigation</font> to gain     a <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>We may become a party to patent <font color="blue">infringement</font> claims     and <font color="blue">litigation</font> or <font color="blue"><font color="blue">interference</font> <font color="blue">proceedings</font></font> declared by the <font color="blue">United States</font>     Patent  and  Trademark  Office,  or  PTO, to determine the priority of     <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>The defense and <font color="blue">prosecution</font> of these matters are <font color="blue">both costly</font> and     time  consuming</td>
    </tr>
    <tr>
      <td>We may need to <font color="blue">commence <font color="blue">proceedings</font> against others</font> to     enforce  our  patents,  to protect our <font color="blue">trade secrets</font> or know-how or to     determine the <font color="blue">enforceability</font>, scope and validity of the <font color="blue">proprietary</font> rights     of others</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">proceedings</font> would</font> result in substantial expense to us and     <font color="blue">significant</font> diversion of <font color="blue">effort by</font> our technical and <font color="blue">management personnel</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">third party</font>, Ovion, Inc, Ovion, which is now a subsidiary of     American Medical Systems, or AMS, brought to our attention a patent and     certain  claims  from  a <font color="blue">pending patent <font color="blue">application</font></font> owned by it</td>
    </tr>
    <tr>
      <td><font color="blue">Ovion     </font>indicated that it believes that the claims of its patent and <font color="blue">application</font>     cover <font color="blue">the Essure </font>system and its use</td>
    </tr>
    <tr>
      <td>On October 23, 2003, we <font color="blue">entered into</font> a     settlement  <font color="blue"><font color="blue">agreement</font> with</font> Ovion pursuant to which we received a sole,     <font color="blue">worldwide license</font> to Ovionapstas <font color="blue">patent rights relative</font> to <font color="blue">the Essure </font>system,     and Ovion may not grant any <font color="blue"><font color="blue">additional</font> such licenses</font> to other parties</td>
    </tr>
    <tr>
      <td>The     <font color="blue">settlement <font color="blue">agreement</font></font> provided for the payment of a royalty to Ovion that     will be equal to 3dtta25prca of the <font color="blue">cumulative net sales</font> of the                                         24       _________________________________________________________________       Essure system in excess of dlra75dtta0 million for a period of <font color="blue">no longer than ten</font>     years</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">settlement <font color="blue">agreement</font></font> provided for a <font color="blue">cash payment</font> of     dlra2dtta0 million in the <font color="blue">fourth quarter</font> of 2003 as a <font color="blue">prepaid royalty</font>, and a     license  fee  of  dlra2dtta0 million  payable  in  our <font color="blue">common stock</font> in equal     <font color="blue">installments</font> in the first and <font color="blue">second quarters</font> of 2004</td>
    </tr>
    <tr>
      <td>Ovion was not granted     any  rights  to  our  <font color="blue">intellectual property</font> pursuant to the settlement     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">settlement <font color="blue">agreement</font></font> was <font color="blue">approved by</font> the US District Court     for the Northern District of California on November 6, 2003</td>
    </tr>
    <tr>
      <td>Although we have reached a <font color="blue">settlement <font color="blue">agreement</font></font> with Ovion, we still     believe that some or all of Ovionapstas claims should be included within our own     patents and we have requested that the PTO to declare an <font color="blue">interference</font></td>
    </tr>
    <tr>
      <td>An     <font color="blue">interference</font> is a <font color="blue">proceeding within</font> the PTO to determine which party was the     first to invent, and which party is thereby entitled to ownership of the     claims</td>
    </tr>
    <tr>
      <td>We believe that we filed our patent <font color="blue"><font color="blue">application</font>s</font> for <font color="blue">the Essure </font>    system before Ovion filed the <font color="blue">application</font> that issued as its patent, and     that we are entitled to any patentable claims now appearing in their patent     that cover our product</td>
    </tr>
    <tr>
      <td>We do not know whether the PTO will declare an     <font color="blue">interference</font>, whether we invented our product prior to Ovionapstas date of     invention, or whether we <font color="blue">will prevail</font> in an <font color="blue">interference</font> proceeding if it is     declared by the <font color="blue">PTO If the PTO </font>declares an <font color="blue">interference</font> in our favor and we     are found to have priority of invention, we may avoid having to pay <font color="blue">Ovion     </font><font color="blue">future royalties on</font> the sales of our product</td>
    </tr>
    <tr>
      <td>An  adverse  <font color="blue">determination</font>  in  new <font color="blue">litigation</font> or <font color="blue">interference</font>     <font color="blue">proceedings</font>  to which we are or may become a <font color="blue">party could</font> subject us to     <font color="blue">significant</font> liabilities to <font color="blue">third parties</font> or require us to <font color="blue">seek licenses from</font>     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Although patent and <font color="blue">intellectual property</font> disputes in the     medical device area have <font color="blue">often been settled through licensing</font> or similar     arrangements, costs <font color="blue">associated with</font> such arrangements may be substantial and     could  include <font color="blue">ongoing royalties</font></td>
    </tr>
    <tr>
      <td>We may be unable to obtain <font color="blue">necessary</font>     <font color="blue">licenses on</font> satisfactory terms, if at all</td>
    </tr>
    <tr>
      <td>Adverse <font color="blue">determination</font>s in a     judicial  or  <font color="blue">administrative proceeding</font> or failure to obtain <font color="blue">necessary</font>     licenses could <font color="blue">prevent us from</font> manufacturing and selling <font color="blue">the Essure </font>system</td>
    </tr>
    <tr>
      <td>One of the patents included in our <font color="blue">license from</font> Target Therapeutics,     a  division  of Boston Scientific Corporation, has been the subject of     reexamination <font color="blue">proceedings</font> in the PTO and an <font color="blue">infringement</font> lawsuit by Target     Therapeutics</td>
    </tr>
    <tr>
      <td>The patent is directed to     <font color="blue">variable stiffness catheters</font> for use with guidewires, as might be used in     our <font color="blue">future product</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Although the PTO </font>reaffirmed the <font color="blue">patent with amended</font>     claims  and the lawsuit was settled, the <font color="blue">patent could</font> be challenged or     invalidated in the future</td>
    </tr>
    <tr>
      <td>If this patent is invalidated, our ability to     <font color="blue">prevent others from using</font> this <font color="blue">proprietary</font> <font color="blue">technology</font> would be <font color="blue">compromised</font></td>
    </tr>
    <tr>
      <td>We may in the future acquire one or more <font color="blue">technologies</font>, products or     companies that <font color="blue">complement</font> our business</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue"><font color="blue">effective</font>ly</font>     integrate these into our business and any <font color="blue">such <font color="blue">acquisition</font> could bring</font>     <font color="blue">additional</font> risks, exposures and <font color="blue">challenges</font> to our company</td>
    </tr>
    <tr>
      <td>If we fail to     manage any <font color="blue">acquisition</font>, our business could be impaired</td>
    </tr>
    <tr>
      <td>Our third-party <font color="blue">manufacture</font>r and we will depend upon <font color="blue">third party</font> and     <font color="blue">single source suppliers</font> for <font color="blue">raw materials</font> and finished goods and we do not     have <font color="blue">forward contracts with</font> many of these suppliers</td>
    </tr>
    <tr>
      <td>We and our <font color="blue">third party</font> <font color="blue">manufacture</font>r purchase both <font color="blue">raw materials</font> used     in our product and finished goods from various suppliers, and we rely on a     single source supplier for one component of our product, the polyester     fiber</td>
    </tr>
    <tr>
      <td>We do not have <font color="blue">formal supply contracts with several key vendors</font> and,     <font color="blue">accordingly</font>, these firms may not continue to supply us or our <font color="blue">third party</font>     <font color="blue">manufacture</font>r with <font color="blue">raw materials</font> or finished goods in <font color="blue">sufficient quantities</font>,     or at all</td>
    </tr>
    <tr>
      <td>Delays <font color="blue">associated with</font> any future <font color="blue">raw materials</font> or finished goods     shortages <font color="blue">could impair</font> our sales of <font color="blue">the Essure </font>system, particularly as our     third-party <font color="blue">manufacture</font>r scales up its <font color="blue">manufacturing activities</font> in support     of <font color="blue">United States</font> and <font color="blue">international</font> commercial sales of <font color="blue">the Essure </font>system</td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________               Health <font color="blue">care reform may limit</font> our return on our product</td>
    </tr>
    <tr>
      <td>The levels of revenue and <font color="blue">profitability</font> of medical device companies     may be <font color="blue">affected by</font> the efforts of <font color="blue">government</font> and <font color="blue">third party</font> payers to     contain or reduce the costs of <font color="blue">health care through various</font> means</td>
    </tr>
    <tr>
      <td>In the     <font color="blue">United States</font>, there have been, and we expect that <font color="blue">there will continue</font> to     be, a number of federal, state and <font color="blue">private proposals</font> to <font color="blue">control health care</font>     costs</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">proposals may</font> contain measures intended</font> to <font color="blue">control public</font> and     private spending on health care, as well as to <font color="blue">provide universal public</font>     access to the <font color="blue">health care system</font></td>
    </tr>
    <tr>
      <td>If enacted, these <font color="blue">proposals may</font> result in     a substantial <font color="blue">restructuring</font> of the <font color="blue">health care delivery system</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant     </font>changes  in  the <font color="blue">United States</font> <font color="blue">health care system</font> are likely to have a     substantial <font color="blue">impact over</font> time on the manner in which we conduct our business     and  could  have  a material adverse effect on our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be exposed to product <font color="blue">liability</font> claims, and we have only     limited <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> and sale of <font color="blue">medical products involve</font> an inherent     risk  of  exposure to product <font color="blue">liability</font> claims and <font color="blue">product recalls</font></td>
    </tr>
    <tr>
      <td>We     currently maintain product <font color="blue">liability</font> insurance with <font color="blue">coverage limits</font> of     dlra10dtta0 million  per  occurrence  and  an  annual  aggregate  maximum of     dlra10dtta0 million, which we believe is comparable to that maintained by other     companies of similar <font color="blue">size serving</font> similar markets</td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot assure</font>     you that product <font color="blue">liability</font> claims in <font color="blue">connection with clinical trials</font> or     commercial  sales  of <font color="blue">the Essure </font><font color="blue">system will</font> not <font color="blue">exceed such insurance</font>     <font color="blue">coverage limits</font> or that <font color="blue">such insurance will continue</font> to be <font color="blue">available on</font>     <font color="blue">commercially reasonable terms</font>, or at all</td>
    </tr>
    <tr>
      <td>Insurance is expensive and in the     <font color="blue">future may</font> not be <font color="blue">available on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>A successful     product <font color="blue">liability</font> claim or series of claims <font color="blue">brought against us</font> in excess of     our <font color="blue">insurance coverage</font>, or a recall of our product, could cause our stock     price to fall</td>
    </tr>
    <tr>
      <td>We may not be able to attract and retain <font color="blue"><font color="blue">additional</font> key management</font>,     sales and marketing and <font color="blue">technical personnel</font> or we <font color="blue">may lose existing key</font>     management, sales and marketing or <font color="blue">technical personnel</font>, which may delay our     <font color="blue">development</font> and <font color="blue">marketing efforts</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a number of key management, sales and marketing and     <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>The loss of the services of one or more <font color="blue">key employees</font>     <font color="blue">could delay</font> the <font color="blue">achievement</font> of our <font color="blue">development</font> and <font color="blue">marketing objectives</font></td>
    </tr>
    <tr>
      <td>Our     success will also <font color="blue">depend on</font> our ability to attract and retain <font color="blue">additional</font>     highly qualified management, sales and marketing and <font color="blue">technical personnel</font> to     meet our <font color="blue">growth goals</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face <font color="blue">intense <font color="blue">competition</font></font></font> for <font color="blue">qualified personnel</font>,     many of whom are often subject to <font color="blue">competing employment offers</font>, and we do not     know whether we will be able to attract and retain <font color="blue">such personnel</font></td>
    </tr>
    <tr>
      <td>We  face  <font color="blue">intense <font color="blue">competition</font></font>, and if we are unable to compete     <font color="blue"><font color="blue">effective</font>ly</font>, demand for <font color="blue">the Essure </font>system may be reduced</td>
    </tr>
    <tr>
      <td>The  medical  device  industry  is  highly  <font color="blue">competitive</font> and is     <font color="blue">characterized by rapid</font> and <font color="blue">significant</font> technological change</td>
    </tr>
    <tr>
      <td>The length of     time required for product <font color="blue">development</font> and <font color="blue">regulatory</font> approval plays an     <font color="blue">important role</font> in a companyapstas <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>As we <font color="blue">commercialize</font>     Essure, we expect to <font color="blue">compete with</font>:          •                 other methods of permanent <font color="blue">contraception</font>, in <font color="blue">particular tubal</font>                 ligation;          •                 other methods of non-permanent <font color="blue">contraception</font>, including devices                 such as intrauterine devices, or IUDs, vaginal rings, condoms                 and  <font color="blue">prescription</font>  drugs  such  as the <font color="blue">birth control</font> pill,                 injectable and <font color="blue">implantable contraceptives</font> and patches; and          •                 other companies that may develop permanent <font color="blue">contraception</font> devices                 that are similar to or otherwise <font color="blue">compete with</font> <font color="blue">the Essure </font>system</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________               We  are  aware  of a company that is in the <font color="blue">clinical stages</font> of     <font color="blue">development</font> for non-incisional permanent <font color="blue">contraception</font> devices</td>
    </tr>
    <tr>
      <td>In addition,     new  <font color="blue">competition</font> and <font color="blue">products may</font> arise due to mergers or <font color="blue">acquisition</font>s     performed <font color="blue">by external parties</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">companies may</font> develop products that     could <font color="blue">compete with</font> <font color="blue">the Essure </font>system</td>
    </tr>
    <tr>
      <td><font color="blue">Competitive </font><font color="blue">factors may</font> render the     Essure system obsolete or non<font color="blue">competitive</font> or <font color="blue">reduce demand</font> for <font color="blue">the Essure </font>    system</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future quarterly</font> results <font color="blue">may fluctuate</font></td>
    </tr>
    <tr>
      <td>Our  future  revenues  and results of <font color="blue">operations</font> <font color="blue">may fluctuate</font>     <font color="blue">significant</font>ly from quarter to quarter and will depend upon, among other     factors:          •                 the <font color="blue">rate at which</font> new physicians are trained;          •                 actions relating to <font color="blue">reimbursement</font> matters;          •                 the <font color="blue">rate at which</font> we establish <font color="blue">United States</font> and <font color="blue">international</font>                 <font color="blue">distributors</font> or marketing partners and the degree of their                 success;          •                 the extent to which <font color="blue">the Essure </font>system gains market <font color="blue">acceptance</font>;          •                 the timing and size of <font color="blue">distributor purchases</font>; and          •                 <font color="blue">introduction</font> of <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>Changes in stock option <font color="blue">accounting</font> rules may <font color="blue">adversely</font> impact our     reported operating results prepared in <font color="blue">accordance</font> with <font color="blue">generally</font> accepted     <font color="blue">accounting</font>  principles, our stock price and our <font color="blue">competitive</font>ness in the     <font color="blue">employee marketplace</font></td>
    </tr>
    <tr>
      <td><font color="blue">Technology </font>companies like ours have a history of <font color="blue">using broad based</font>     <font color="blue">employee stock option programs</font> to hire, incentivize and retain our workforce     in a <font color="blue">competitive</font> marketplace</td>
    </tr>
    <tr>
      <td>Statement of Financial Accounting Standards,     or SFAS, Nodtta 123 allowed companies the choice of <font color="blue">either using</font> a <font color="blue">fair value</font>     method of <font color="blue">accounting</font> for options, which would result in <font color="blue">expense recognition</font>     for all <font color="blue">options granted</font>, or using an intrinsic value method, as prescribed     by Accounting Principles Board Opinion Nodtta 25,  &amp;quote Accounting for Stock Issued     to Employees &amp;quote , or APB 25, with a pro forma <font color="blue">disclosure</font> of the <font color="blue"><font color="blue">impact on</font> net</font>     income (loss) of using the <font color="blue">fair value</font> option <font color="blue">expense recognition</font> method</td>
    </tr>
    <tr>
      <td>We     had elected to apply APB 25 and <font color="blue">accordingly</font> we <font color="blue">generally</font> do not recognize     any <font color="blue">expense with respect</font> to <font color="blue">employee stock options as long as such options</font>     are granted at exercise prices equal to the <font color="blue">fair value</font> of our <font color="blue">common stock</font>     on the date of grant</td>
    </tr>
    <tr>
      <td><font color="blue">In December </font>2004, the Financial Accounting Standards Board, or FASB,     issued SFAS Nodtta 123(R)  &amp;quote Share-Based Payments &amp;quote</td>
    </tr>
    <tr>
      <td>We adopted this <font color="blue">statement on</font>     January 1, 2006, which is the <font color="blue">first annual</font> reporting period after June 15,     2005</td>
    </tr>
    <tr>
      <td>This statement will have a <font color="blue">significant</font> <font color="blue">impact on</font> our <font color="blue">consolidated</font>     statement of <font color="blue">operations</font> as we will be required to expense the <font color="blue">fair value</font> of     our <font color="blue">stock options rather than</font> disclosing the <font color="blue">impact on</font> our <font color="blue">consolidated</font>     result of <font color="blue">operations</font> within our footnotes in <font color="blue">accordance</font> with the <font color="blue">disclosure</font>     provisions of SFAS Nodtta 123</td>
    </tr>
    <tr>
      <td>This will result in lower reported <font color="blue">earnings per</font>     share or in higher reported <font color="blue">losses per</font> share, <font color="blue">which could negatively impact</font>     our  <font color="blue">future stock price</font></td>
    </tr>
    <tr>
      <td>In addition, this could impact our ability to     <font color="blue">utilize broad based employee stock</font> plans to <font color="blue">reward employees</font> and could     result in a <font color="blue">competitive</font> disadvantage to us in the <font color="blue">employee marketplace</font></td>
    </tr>
    <tr>
      <td>Future changes in financial <font color="blue">accounting</font> standards or practices or     <font color="blue">existing taxation rules</font> or <font color="blue">practices may</font> cause <font color="blue">adverse unexpected revenue</font>     <font color="blue">fluctuations</font> and affect our reported results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>A  change  in <font color="blue">accounting</font> standards or practices or a change in     <font color="blue">existing taxation rules</font> or practices can have a <font color="blue">significant</font> effect on our     reported results and <font color="blue">may even affect</font> our reporting of <font color="blue">transactions</font> completed     before the change is <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>New <font color="blue">accounting</font> pronouncements and taxation     rules and varying <font color="blue">interpretations</font> of <font color="blue">accounting</font> pronouncements and taxation     practice have occurred and may                                         27       _________________________________________________________________       occur in the future</td>
    </tr>
    <tr>
      <td>Changes to existing rules or the questioning of current     <font color="blue">practices may</font> <font color="blue">adversely</font> affect our reported financial results or the way we     conduct our business</td>
    </tr>
  </tbody>
</table>